These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 32116658)

  • 21. Evaluation of the Performance of the Gulf Cooperation Council Centralised Regulatory Review Process: Strategies to Improve Product Authorisation Efficiency and Quality.
    Hashan HM; Al-Muteb SK; Alismail IA; Alsaleh ON; Alkherb ZM; McAuslane N; Walker SR
    Pharmaceut Med; 2022 Aug; 36(4):223-231. PubMed ID: 35767216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the Food and Drugs Authority, Ghana Regulatory Review Process: Challenges and Opportunities.
    Owusu-Asante M; Darko DM; Asamoah-Okyere KD; Asante-Boateng S; Kermad A; Walker S; Salek S
    Ther Innov Regul Sci; 2023 Mar; 57(2):372-385. PubMed ID: 36352343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2018 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2019 Feb; 18(2):85-89. PubMed ID: 30710142
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessing the Quality of Decision Making in the Development and Regulatory Review of Medicines: Identifying Biases and Best Practices.
    Bujar M; Donelan R; McAuslane N; Walker S; Salek S
    Ther Innov Regul Sci; 2017 Mar; 51(2):250-256. PubMed ID: 30231720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of Regulatory Decision-Making Practices: Issues Facing Companies and Agencies.
    Bujar M; McAuslane N; Salek S; Walker S
    Ther Innov Regul Sci; 2016 Jul; 50(4):487-495. PubMed ID: 30227024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Turkish Medicines and Medical Devices Agency: Comparison of Its Registration Process with Australia, Canada, Saudi Arabia, and Singapore.
    Mashaki Ceyhan E; Gürsöz H; Alkan A; Coşkun H; Koyuncu O; Walker S
    Front Pharmacol; 2018; 9():9. PubMed ID: 29422861
    [No Abstract]   [Full Text] [Related]  

  • 27. The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making.
    Donelan R; Walker S; Salek S
    Front Pharmacol; 2016; 7():180. PubMed ID: 27468267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Performance of the Turkish Regulatory Agency: Recommendations for Improved Patients' Access to Medicines.
    Koyuncu O; Gursoz H; Alkan A; Cetintas HC; Pasaoglu T; Mashaki Ceyhan E; Walker S
    Front Pharmacol; 2019; 10():1557. PubMed ID: 32116658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvements.
    Miletic N; Adam S; Acquah J; Aziz Z; Joos A; Mwangi JM
    Front Med (Lausanne); 2023; 10():1207954. PubMed ID: 37731723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The harmonization of the regulation of blood products: a European perspective.
    Seitz R; Heiden M; Nübling CM; Unger G; Löwer J
    Vox Sang; 2008 May; 94(4):267-76. PubMed ID: 18179678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From molecule to market access: drug regulatory science as an upcoming discipline.
    Gispen-de Wied CC; Leufkens HGM
    Eur J Pharmacol; 2013 Nov; 719(1-3):9-15. PubMed ID: 23891846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The South African Regulatory System: Past, Present, and Future.
    Keyter A; Banoo S; Salek S; Walker S
    Front Pharmacol; 2018; 9():1407. PubMed ID: 30618735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ICH guidelines--implementation of the 3Rs (refinement, reduction, and replacement): incorporating best scientific practices into the regulatory process.
    Ohno Y
    ILAR J; 2002; 43 Suppl():S95-8. PubMed ID: 12388859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Procedure for the marketing authorization of an antibacterial agent].
    López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of immunological veterinary medicinal products in the European Union.
    Brunko P
    Rev Sci Tech; 1995 Dec; 14(4):1133-41. PubMed ID: 8639951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
    Hartmann M; Mayer-Nicolai C; Pfaff O
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Difference between Approval Processes for Medicinal Products and Medical Devices in Europe.
    Marshall J; Morrill K; Gobbe M; Blanchard L
    Ophthalmologica; 2021; 244(5):368-378. PubMed ID: 34062546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Building a Better Approach for the Benefit of Patients: 10 Pillars to Strengthen Regulatory Review Systems Globally.
    O'Brien J; Lumsden RS; Diehl DH; Macdonald JC
    Ther Innov Regul Sci; 2020 Mar; 54(2):283-292. PubMed ID: 32072580
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.